Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Electromed (AMEX: ELMD) Reports Q4 FY 2026 Revenue Up 11.6% to $19.4M

Electromed, Inc. (AMEX: ELMD) achieved a record net revenue of $19.4 million during Q4 FY 2026, reflecting an impressive 11.6% increase compared to the $17.4 million reported in the same quarter last fiscal year. This achievement highlights the company's sustained growth trajectory and operational …

Vinay Lochav | 26 August 2026

Spyre Therapeutics (NASDAQ: SYRE) Reports Positive Phase 2 Results for SPY072 in RA

Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced on August 25, 2026, that its Phase 2 SKYWAY basket trial's rheumatoid arthritis (RA) sub-study delivered promising topline results for SPY072. Both the Low and High Dose of SPY072 demonstrated statistically significant improvements over placebo in various key …

Vinay Lochav | 26 August 2026

Bicara Therapeutics (NASDAQ: BCAX) Signs Sublease for 35,090 Square Feet HQ

Bicara Therapeutics Inc. (NASDAQ: BCAX) has finalized a sublease agreement for roughly 35,090 square feet of office space, designed to serve as its new headquarters in Boston. This strategic move takes place at 10 St. James Avenue, positioning the firm for enhanced operational capabilities. …

Vinay Lochav | 26 August 2026

HHS Adds Deputy Commissioners as Drug Innovation Advances

HHS's decision to establish two new deputy commissioner roles at the FDA marks a key shift in the agency's approach to innovation in healthcare. The primary focus will be on technology applications and drug development, which are essential as the industry evolves. This move …

Vinay Lochav | 26 August 2026

Theravance Biopharma (NASDAQ: TBPH) Reports Phase 3 Study Findings on Ampreloxetine

Theravance Biopharma, Inc. (NASDAQ: TBPH) released findings from the Phase 3 CYPRESS study of ampreloxetine, revealing that the primary endpoint change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score at week 8 was not statistically significant. This result suggests challenges in the overall …

Vinay Lochav | 26 August 2026

M. Fatih Karatas Steps Into Interim CEO Role at Abpro Holdings

Miles Suk has resigned as Chief Executive Officer of Abpro Holdings, Inc. a move effective August 19, 2026. This resignation is notable as it occurred without any reported disagreements concerning the company's operations or policies. Following his departure, theBoard of Directorshas appointed M. Fatih …

Vinay Lochav | 26 August 2026

Tonix Pharmaceuticals (NASDAQ:TNXP) Climbs Nearly 10% as Tonmya Sales Accelerate

Tonix Pharmaceuticals (NASDAQ:TNXP) climbed 9.72% in a session that put the long-suffering specialty-pharma name back on the most-active lists, extending a stretch of renewed attention around its newly launched fibromyalgia therapy.

Nitish Kishor | 26 August 2026

TherapeuticsMD (NASDAQ:TXMD) Jumps 10% on a Small but Meaningful Return to Profit

TherapeuticsMD, Inc. (NASDAQ:TXMD), a women's-health company reinvented as a lean licensing and royalty business, climbed 10.14% in a session that spotlighted one of the market's quieter micro-cap comebacks. The move reflected renewed interest in a name that has transformed itself almost beyond recognition.

Nitish Kishor | 26 August 2026

Treace Medical (NASDAQ:TMCI) Rallies 10% on Signs of Stabilizing Growth

Treace Medical Concepts (NASDAQ:TMCI), the company behind the Lapiplasty bunion-correction system, surged 10.07% as investors bet on a cautious rebound following a challenging stretch for the foot-and-ankle specialist. The move suggested the market is beginning to look past a period of decelerating growth.

Nitish Kishor | 26 August 2026

Is the Medical-Tech Rally Losing Steam? Tenon Medical (NASDAQ:TNON) Falls 11%

● TNON shares fell 10.94% following a turbulent stretch that included a 1-for-35Reverse Stock Splitexecuted to maintain Nasdaq's minimum-bid compliance.

Nitish Kishor | 26 August 2026
Support

Hi! How can we help you today?

Loading…